AI Trading NASDAQ Fri, 09 Feb

Dear Reader,

The featured asset for today is TG Therapeutics Inc. (TGTX), with a potential return of 826.79% if traded between 2021-03-22 and 2024-01-08 using AI strategy. The average trade made 63.6% in 44.0 days, with a total of 13.0 positions taken during this period. The current trading idea for TGTX suggests a STRONGBUY since 2024-02-08 with a buy price target of $15.68, based on a model with a historical accuracy of 0.64 in predicting upward trends within the following 2 weeks. The consensus price target from analysts is $20.0.

TG Therapeutics Inc. (TGTX) is a biopharmaceutical company that specializes in developing and commercializing novel treatments for B-cell malignancies and autoimmune diseases. With its headquarters in New York City, the company has become a prominent player in the healthcare industry, gaining recognition for its innovative approach to treating these diseases.

Company Overview and Markets
TG Therapeutics Inc. was founded in 1993 and has since grown to become a leading biopharmaceutical company in the United States. The company’s main focus is on developing and commercializing treatments for B-cell malignancies, such as lymphoma and leukemia, as well as autoimmune diseases like multiple sclerosis and rheumatoid arthritis.

The company’s pipeline includes various drug candidates that are currently in different stages of development, with some already approved by the FDA for commercial use. These treatments aim to target specific molecules and pathways involved in B-cell malignancies and autoimmune diseases, providing more effective and targeted therapies for patients.

TG Therapeutics Inc. primarily operates in the life sciences sector, specifically in the pharmaceutical preparations industry. The company has a strong presence in the US market and is actively expanding its reach globally.

Historic Company Performance and Share Price Performance
Over the years, TG Therapeutics Inc. has seen significant growth and development, both in terms of its financial performance and share price. The company’s revenue has been steadily increasing, with a revenue of $5.03 million reported in the latest quarter of 2022, compared to $4.98 million in the same quarter of the previous year.

The company’s share price has also shown a positive trend, with a 52-week high of $19.58 and a 52-week low of $3.48. As of February 8, 2024, the company’s share price stands at $15.68, representing a significant increase from its previous year’s performance.

Current Company Information
TG Therapeutics Inc.’s current information, as of February 8, 2024, is as follows:

– Symbol: TGTX
– Asset Type: Common Stock
– Exchange: NASDAQ
– Currency: USD
– Country: USA
– Sector: Life Sciences
– Industry: Pharmaceutical Preparations
– Address: 2 Gansevoort Street, 9th Floor, New York, NY, US
– Fiscal Year End: December
– Latest Quarter: 2022-09-30
– Market Capitalization: $2.78 billion
– EBITDA: -$233.41 million
– PE Ratio: None
– PEG Ratio: 0
– Book Value: $0.75
– Dividend Per Share: $0
– Dividend Yield: 0
– EPS: -$2.458
– Revenue Per Share TTM: $0.037
– Profit Margin: 0
– Operating Margin TTM: -46.5%
– Return on Assets TTM: -0.466%
– Return on Equity TTM: -1.159%
– Revenue TTM: $5.03 million
– Gross Profit TTM: $5.89 million
– Diluted EPS TTM: -$2.458
– Quarterly Earnings Growth YOY: 0%
– Quarterly Revenue Growth YOY: -0.954%
– Analyst Target Price: $20
– Trailing PE: –
– Forward PE: –
– Price to Sales Ratio TTM: 249.27
– Price to Book Ratio: 10.88
– EV to Revenue: 198.82
– EV to EBITDA: -4.349
– Beta: 2.016
– 52-Week High: $19.58
– 52-Week Low: $3.48
– 50-Day Moving Average: $12.18
– 200-Day Moving Average: $7.69
– Shares Outstanding: 145.34 million
– Dividend Date: None
– Ex-Dividend Date: None

In conclusion, TG Therapeutics Inc. (TGTX) has established itself as a strong player in the biopharmaceutical industry, with a focus on developing innovative treatments for B-cell malignancies and autoimmune diseases. With its current financial performance and share price performance, the company shows potential for further growth and success in the future.

Symbol: TGTX
AssetType: Common Stock
Name: TG Therapeutics Inc
Description: TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in New York, New York.
CIK: 1001316
Exchange: NASDAQ
Currency: USD
Country: USA
FiscalYearEnd: December
LatestQuarter: 2022-09-30
MarketCapitalization: 2784171000
EBITDA: -233414000
PERatio: None
PEGRatio: 0
BookValue: 0.75
DividendPerShare: 0
DividendYield: 0
EPS: -2.458
RevenuePerShareTTM: 0.037
ProfitMargin: 0
OperatingMarginTTM: -46.5
ReturnOnAssetsTTM: -0.466
ReturnOnEquityTTM: -1.159
RevenueTTM: 5026000
GrossProfitTTM: 5899000
DilutedEPSTTM: -2.458
QuarterlyEarningsGrowthYOY: 0
QuarterlyRevenueGrowthYOY: -0.954
AnalystTargetPrice: 20
TrailingPE: –
ForwardPE: –
PriceToSalesRatioTTM: 249.27
PriceToBookRatio: 10.88
EVToRevenue: 198.82
EVToEBITDA: -4.349
Beta: 2.016
52WeekHigh: 19.58
52WeekLow: 3.48
50DayMovingAverage: 12.18
200DayMovingAverage: 7.69
SharesOutstanding: 145342000
DividendDate: None
ExDividendDate: None

Date Symbol Prediction Model Accuracy Price Target Analyst Target
2024-02-08 TGTX STRONGBUY 0.64 15.68 20.0
2024-01-22 TGTX MEDIUMBUY 0.64 16.22 20.0

More AI Trading NASDAQ Fri, 09 Feb buys

You must be logged in to view this content. Log In No account? Register  for Free.  

AI Trading NASDAQ Fri, 09 Feb sells

You must be logged in to view this content. Log In No account? Register  for Free.  

Back-testing and model summaries

You must be logged in to view this content. Log In No account? Register  for Free.  

Thanks for subscribing and happy investing!

The Third Perspective Team